In these doldrums, at least the post FDA doldrums,
there are a lot of areas for concern and optimism
There is the known patent life for specific compounds discovered but two things for thought; is this the same type of patent life as what oxycodone, xyprexa has/had; secondly, don't drug companies find new ways to extend patents, vytorin.
Could Org-24448 finish phase 3 and go to market then a new study-RD/other cause an extension of the patent,, or maybe a combination pain reliever/org-24448 or other for a way to extend a patent.
Speaking of Org-24448 and Org-26576, why would they spend the money for continuing the trials if 1-they would not be able to bring them to market 2-if they thought ampakines did not show adequate risk reward for them
What does the continuation mean for Cortex- 1. money if brought to market 2. further collaboration for additional companies, merger, development agreement 3. ?Nixing the relevancy of near term solid financial ground. 4. Reducing the relevancy of RD results, extremely relevant, but the Org components are some nice extra logs in the fireplace.
One other thing on my mind, Cortex seems to do a great job on the studies which they design and complete, they have mostly done toxicology studies and animal studies. Maybe a review of all human studies they have done would be a good area to review.
Darpa would need to be considered as an outside study done by a non-biopharm company, and a political company none the less. Has anyone read results from a painreliever study in patients without pain or a BP med study in people without BP problems? Well, may we have read results of an alertness study for a possible alertness med when the study is done in a way to where actual alertness problems never truly were allowed to be present.
